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Abstract
We have performed a metabolite quantitative trait locus (mQTL) study of the
1H nuclear magnetic resonance spectroscopy
(
1H NMR) metabolome in humans, building on recent targeted knowledge of genetic drivers of metabolic regulation. Urine
and plasma samples were collected from two cohorts of individuals of European descent, with one cohort comprised of
female twins donating samples longitudinally. Sample metabolite concentrations were quantified by
1H NMR and tested for
association with genome-wide single-nucleotide polymorphisms (SNPs). Four metabolites’ concentrations exhibited
significant, replicable association with SNP variation (8.6610
211,p,2.8610
223). Three of these—trimethylamine, 3-amino-
isobutyrate, and an N-acetylated compound—were measured in urine. The other—dimethylamine—was measured in
plasma. Trimethylamine and dimethylamine mapped to a single genetic region (hence we report a total of three implicated
genomic regions). Two of the three hit regions lie within haplotype blocks (at 2p13.1 and 10q24.2) that carry the genetic
signature of strong, recent, positive selection in European populations. Genes NAT8 and PYROXD2, both with relatively
uncharacterized functional roles, are good candidates for mediating the corresponding mQTL associations. The study’s
longitudinal twin design allowed detailed variance-components analysis of the sources of population variation in
metabolite levels. The mQTLs explained 40%–64% of biological population variation in the corresponding metabolites’
concentrations. These effect sizes are stronger than those reported in a recent, targeted mQTL study of metabolites in
serum using the targeted-metabolomics Biocrates platform. By re-analysing our plasma samples using the Biocrates
platform, we replicated the mQTL findings of the previous study and discovered a previously uncharacterized yet
substantial familial component of variation in metabolite levels in addition to the heritability contribution from the
corresponding mQTL effects.
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Expression quantitative trait loci (eQTL) studies have proved a
powerful aid to functional genomics, with many thousand genetic
loci now highlighted that affect RNA transcription levels or
splicing in human tissues [1]. eQTL studies have accelerated the
characterization of biological mechanisms governing gene regula-
tion [2–5], and genome-wide multi-tissue maps of known eQTLs
have clarified the biological basis for a proportion of disease-
associated [6–7] and positively selected [8] loci (e.g. http://eqtl.
uchicago.edu/cgi-bin/gbrowse/eqtl/). Genetic variation at eQT
Ls can be incorporated into network models that help define
dependence between genotypes, molecular traits, environment,
and physiological states [9–10]. The success of eQTL studies
points to the potential value in applying the eQTL paradigm to
other molecular traits besides mRNA transcript levels [11–14]. In
the current study, we associate genome-wide genetic variation with
concentrations of metabolites, small molecules involved in biochem-
ical processes in living systems, which can be measured in samples
such as biofluids and tissue extracts using
1H nuclear magnetic
resonance spectroscopy (
1H NMR) [15–17], or by the Biocrates
platform. (For convenience, we use the term ‘Biocrates platform’ in
the current paper to refer to the targeted-metabolomic platform
using flow-injection tandem mass spectrometry—FIA-MS—devel-
oped by Biocrates Life Sciences [14,18].)
Metabolites are mechanistically further removed from the
genome than are mRNAs, creating an important qualitative
distinction between metabolite QTL (mQTL) and eQTL studies.
The mRNA-to-gene mapping is a useful property of eQTL studies,
allowing the searchfora ciseQTLofeach mRNAtobefocusedona
relatively small, gene-centred region. Moreover, most known
eQTLs are cis-acting single-nucleotide polymorphisms (SNPs), lying
usually within tens of kb of the genes whose expression they
influence [1,5]. Whilst metabolite concentrations are influenced
indirectly by mRNA and protein expression, there is not typically a
one-to-one metabolite-to-gene correspondence known, or indeed
expected, a priori. An mQTL study tests variation in each metabolite
for association with genome-wide genetic variation. As such a large
number of tests is performed, effect sizes must be substantially larger
to be reach statistical significance. Thus, as well as being potentially
rarer, mQTLs are typically more difficult to detect than eQTLs of
equivalent effect size.
A number of recent studies have reported mQTLs for serum
metabolite concentrations in humans [14,19]. Illig et al. [14]
genotyped 1,809 individuals of Northern European ancestry at
genome-wide single-nucleotide polymorphisms (SNPs), and deter-
mined concentrations of 163 metabolites in serum samples from
the same individuals, using the Biocrates platform (targeted
metabolomics using FIA-MS) [18]. They went on to quantify
association between each SNP and a derived set of 26,569
metabolic traits (including 163 raw metabolite concentrations and
all pair-wise metabolite concentration ratios). They discovered
nine significant, replicable associations between metabolite
concentration ratios and SNPs. We demonstrate in the current
paper that their study [14] was well powered to detect mQTLs
explaining approximately 3% or more of population variation in
those serum metabolites targeted by Biocrates. In the current
paper the effect size of an mQTL is defined to be the proportion of
population variation in metabolite concentration that is explained
by genetic variation at the corresponding mQTL SNP.
The primary question addressed by our study is: ‘Are there
1H
NMR-detectable metabolites in urine or plasma that are strongly
influenced by common single-locus genetic variation?’ To this end,
we performed an mQTL-discovery study using
1H NMR to
analyse plasma and urine samples from multiple cohorts (see
Results and Materials and Methods).
1H NMR is an untargeted,
discovery-driven approach that covers many important substances
involved in major biochemical functions and key intermediary
processes [16]. Our study demonstrates the existence of mQTLs of
larger effect size than those reported in [14] for the untargeted set
of metabolites detectable by
1H NMR, in urine as well as plasma
(urine is previously unexplored for mQTLs). The current paper’s
secondary aim was to provide further support for the findings of
[14]. We conducted replication of the findings of [14], using the
Biocrates platform to assay our set of plasma samples. We
replicated additional mQTLs, and characterized the familial
component of biological variation in mQTL-driven metabolite
levels, augmenting the mQTL-derived heritability.
Results
Cohorts and data acquisition
We collected plasma and urine samples from participants across
two cohorts—MolTWIN and MolOBB—as part of the MolPAGE
programme. The MolTWIN cohort comprised 142 female twins
of Northern European descent, who donated samples longitudi-
nally. The MolOBB cohort comprised 69 participants in the
Oxford Biobank (OBB) [20].
For all participants across both cohorts we acquired:
1H NMR
spectra on plasma and urine samples; Biocrates-platform metab-
olite concentration data on plasma samples; and genome-wide
SNP data (see Materials and Methods).
Extraction of metabolite peaks from spectra and
genome-wide scan (
1H NMR)
Analysis of a biological sample by
1H NMR provides a spectrum,
which is comprised of the superimposed spectral profiles of
individual metabolites; a metabolite’s profile is made up of peaks
from each chemically distinct hydrogen atom in the corresponding
molecule. The peak position of a given hydrogen on the horizontal
(frequency) axis is known as a chemical shift and is quoted in parts per
million (ppm, often termed a d value) from that of a reference
substance. The concentration of each detectable hydrogen-
containing metabolite can be inferred from the area under its total
Author Summary
Physiological concentrations of metabolites—small mole-
cules involved in biochemical processes in living systems—
can be measured and used to diagnose and predict
disease states. A common goal is to detect and clinically
exploit statistical differences in metabolite concentrations
between diseased and healthy individuals. As a basis for
the design and interpretation of case-control studies, it is
useful to have a characterization of metabolic diversity
amongst healthy individuals, some of which stems from
inter-individual genetic variation. When a single genetic
locus has a sufficiently strong effect on metabolism, its
genomic position can be determined by collecting
metabolite concentration data and genome-wide geno-
type data on a set of individuals and searching for
associations between the two data sets—a so-called
metabolite quantitative trait locus (mQTL) study. By so
tracing mQTLs, we can identify the genetic drivers of
metabolism, characterize how the nature or quantity of the
corresponding expressed protein(s) feeds forward to
influence metabolite levels, and specify disease-predictive
models that incorporate mutual dependence amongst
genetics, environment, and metabolism.
mQTLs Exhibit Genetic Evidence of Selection
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contributing to it is known. We preprocessed spectra, and extracted
a total of 526 metabolite peaks from each pair of samples, i.e. the
twosamples(plasmaand urine)donated byaparticipantonavisitto
the clinic. These peaks represent fewer than 526 metabolites with
some redundancy (see Materials and Methods).
Using data from the MolTWIN cohort, each of the 526
metabolite peaks was tested for association with 2,541,644
autosomal SNPs (of which 2,245,627 were imputed and 296,017
were typed). In order to address both multiple testing and the
kinship of twin pairs, we used a permutation-based procedure,
constraining the genome-wide false-discovery probability to be less
than 0.001 for each metabolite peak’s genome-wide scan.
We detected, and then replicated, four metabolites driven
largely by SNP variation (8:6|10{11vpv2:8|10{23), across
three genomic regions, explaining between 40%–64% of biological
population variation in these four metabolites’ concentrations.
Genetic details of the hit regions are shown in Table 1. Note that
there are only three hit regions for the four metabolites because
two metabolites mapped to a single, shared region. One of the
mQTLs is in strong linkage disequilibrium (LD, reviewed in [21])
with SNP variation associated with renal function [22–23]. We
found that two of the three mQTL regions exhibited genetic
evidence of having experienced strong, recent positive selection in
European populations (further details of these findings are
presented later, in dedicated sections in Results and Discussion).
Identification of metabolites (
1H NMR)
We proceeded to identify as many of the mQTL-driven
metabolites as possible using a combination of: the web-based
human metabolome database [24], our in-house developed
database, statistical total correlation analysis [25], and other
literature [26]. We unambiguously identified three out of four
metabolites, and partially identified the fourth. The mQTL at
chromosome 10q24.2 had two associated metabolites, identified as
trimethylamine in urine (TMAu), and dimethylamine in plasma
(DMAp). The mQTL at 5p13.2 affects urine concentration of 3-
amino-isobutyrate (a.k.a. b-amino-isobutyrate, denoted by
BAIBu).
The mQTL at 2p13.1 associates with concentrations of one or
more urine metabolites that we partially identified as N-acetylated
compound(s): X.NH.CO.CH3, with X unknown; we denote this
set of one or more metabolites as N-ACu. We were unable to
annotate N-ACu unambiguously despite conducting a number of
additional experiments, including: seven experiments in which we
spiked candidate compounds into selected urine samples and then
re-measured the
1H NMR spectra; solid phase extraction
experiments on urine samples in which we attempted to separate
out N-ACu and thus aid its identification; and 2-dimensional
1H-
13C heteronuclear single quantum coherence NMR spectros-
copy experiments on selected urine samples.
Table 2 summarizes these metabolite annotations. Figure S1
displays the three mQTL-driven urine metabolite peaks on the
same scale, allowing visual assessment of their relative size.
Mixed-effects analysis of hit regions (
1H NMR)
We went on to characterize more accurately each metabolite’s
associations with SNPs within 200 kb of the hit regions. We used a
linear mixed-effects model to account for: the sharing of genes and
environment across twins, the collection of multiple samples
longitudinally from some subjects, and the technical replication of
each biological sample (see Materials and Methods).
Under this model, we calculated p-values for the test of no
association between the metabolite and each regional SNP in turn.
Figure 1, Figure 2, Figures S2 and S3 display the p-values for all
regional tests of association superimposed on patterns of LD and
the positions of genes. The details of association of each metabolite
with its most strongly associated SNP are listed in Table 3, while
Table S1 contains association results for SNPs within 200 kb of hit
regions. The relationship between metabolite concentration and
genotype is presented graphically in Figure 3.
Variance decomposition of metabolite concentrations
(
1H NMR and Biocrates)
For
1H NMR mQTLs, we estimated the proportion of
biological variation in the metabolite’s concentration explained
by the corresponding mQTL SNP, and decomposed the
remaining variation into familial, individual-environmental, and
longitudinally fluctuating (visit) effects (Figure 4, Table 4, and
Materials and Methods). The familial component of variation
modelled the combined effects of genome-wide identity-by-descent
genetic sharing, and common environment (i.e. environmental
influences shared by twins after their conception). The individual-
visit and common-visit components of variation modelled the
longitudinal fluctuations between sample-donation visits that were
respectively non-shared and shared by twins in a pair (the
common-visit effect was included in the model because twins
visited the clinic in pairs).
The proportions shown in Figure 4 and Table 4 are proportions
of phenotypic variance after the experimental variance has been
removed. It was useful to extract the experimental variance prior
to comparison across platforms, as the primary focus was on the
Table 1. Genetic details of
1H NMR mQTL regions.
Allele Frequency
a
ID SNP Chr Position
b Local Genes Alleles
c MolTWIN CEU
d YRI
e
TMAu rs7072216 10 100156853 PYROXD2 (C10orf33) C/T 0.35 0.25 0.86
N-ACu rs9309473 2 73743982 ALMS1, NAT8, TPRKB, DUSP11 G/A 0.25 0.21 0.59
BAIBu rs37369 5 35037115 AGXT2 T/C 0.10 0.09 0.67
DMAp rs6584194 10 100160399 PYROXD2 (C10orf33) C/T 0.35 0.37 0.90
aFrequency of minor allele (where minor/major alleles are defined by their frequency in the Northern European HapMap-CEU population [29]).
bNCBI build 37 coordinates.
cMinor/major allele in HapMap-CEU.
dFrequency in Northern European (HapMap-CEU) population.
eFrequency in African (HapMap-YRI) population [29].
doi:10.1371/journal.pgen.1002270.t001
mQTLs Exhibit Genetic Evidence of Selection
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experimental variation associated with the measurement process.
The mQTLs explained 40%–64% of biological population
variation in the corresponding
1H NMR metabolite levels.
We also performed a variance decomposition of the metabolic
traits, quantified on the Biocrates platform, for which mQTLs
were identified in [14] (Figure 4, Table 4, and Materials and
Methods). The Biocrates-platform mQTLs explained up to 35% of
biological variation in the corresponding metabolic traits (smaller
effect sizes than for the
1H NMR mQTLs). Our results
qualitatively extended the findings of [14]: the current study’s
design allowed the decomposition of the component of variation in
metabolite concentration that was not explained by the mQTL
itself (see Discussion).
To investigate potential bias in effect-size estimates (the
‘‘winner’s curse’’ phenomenon [27]), we compared effect-size
Table 2. Annotation of mQTL-driven
1H NMR-detectable metabolites.
ID Data Set Peak ppm Interval Metabolite Formula
TMAu Urine Standard 1d (2.857 - 2.87)
a trimethylamine C3H9N
N-ACu Urine Standard 1d (2.034 - 2.042) N-acetylated compound(s) X.NH.CO.CH3
b
BAIBu Urine Standard 1d (1.185 - 1.191) 3-amino-isobutyrate CH3.CH.(CH2.NH2).COOH
DMAp Plasma Spin-Echo (2.7 - 2.724) dimethylamine (CH3)2.NH
aWe observed frequency shifts in TMA peaks between the MolTWIN and MolOBB data sets, attributable to inter-study differences in experimental conditions, such as
sample pH or temperature. To align the peaks across cohorts, a different peak interval was used for TMAu in the MolOBB data: (2.86 – 2.88).
bThe metabolite was partially identified as an N-acetylated compound: X.NH.CO.CH3, with X unknown.
doi:10.1371/journal.pgen.1002270.t002
Figure 1. Hit region for N-ACu. Top: location of genes, with rectangles denoting the position of exons. Middle: log-transformed p-values
({log10(p)) for the test of association of the metabolite’s concentration with each SNP in the region. Bottom: LD between each pair of SNPs in the
region, with the colour scale for r2 superimposed.
doi:10.1371/journal.pgen.1002270.g001
mQTLs Exhibit Genetic Evidence of Selection
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Biocrates-platform mQTLs (Figure S4), and for the
1H NMR
mQTLs (Figure S5). We found there to be a good degree of
consistency in effect-size estimates between discovery and
replication studies.
Quantification of study power (
1H NMR and Biocrates)
Figure 5 relates the detectable effect size (the proportion of
variance in concentration explained by the mQTL SNP,
quantified by r2) to the sample size for each study (power
calculations used the GeneticsDesign R package). Our study had
power to detect associations with approximately r2w32%, while
[14] had power to discover much smaller effects (approximately
r2w3%). Better powered studies such as [14] have the potential to
offer further interesting insights into the mQTL basis of the
1H
NMR metabolome.
Proximity of mQTLs to known GWAS SNPs (
1H NMR)
We searched within 200 kb of each metabolite’s hit region for
SNPs previously associated with phenotypes in GWASs [28]. SNP
rs13538 is in strong LD with the N-ACu hit region at chromosome
2p13.1 (r2~1 between rs13538 and rs9309473 in the HapMap 3
individuals of Northern European ancestry, i.e. HapMap-CEU
[29]). Variation at rs13538 has been shown to correlate with
serum creatinine concentration and other measures of renal
impairment, as well as with susceptibility to chronic kidney disease
[22–23].
Coincidence of mQTLs with positively selected regions
(
1H NMR and Biocrates)
Upon surveying the literature related to genes in the region of the
N-ACu mQTL, we realized that several papers had highlighted this
particular region as carrying one of the strongest signatures of
selection that has been discovered in the human genome (see, e.g.,
[8,30]). This led us to check all known mQTLs for coincidence with
positively selected regions (as identifiedby the genome-wide scan for
such regions in [8]; see also [31] for a review of the detection and
relevance of the genetic signature of natural selection).
We compared the locations of all mQTLs discussed in the
current paper to the positively selected loci identified in [8]. Two
of our three replicated mQTL hits were within such regions (the
mQTL for N-ACu, and the mQTL that affects both TMAu and
DMAp). We also examined the genomic locations of each of Illig
et al.’s 13 replicated mQTLs (see dedicated section below on
Figure 2. Hit region for TMAu. Top: location of genes, with rectangles denoting the position of exons. Middle: log-transformed p-values
({log10(p)) for the test of association of the metabolite’s concentration with each SNP in the region. Bottom: LD between each pair of SNPs in the
region, with the colour scale for r2 superimposed.
doi:10.1371/journal.pgen.1002270.g002
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regions as identified in [8].
Analysis of TMAu and DMAp mQTL (
1H NMR)
SNPs significantly associated with TMAu and DMAp fall within
a haplotype block of approximately 40 kb at chromosome
10q24.2, which contains the PYROXD2 gene, a probable pyridine
nucleotide-disulphide oxidoreductase gene, previously named
C10orf33 (see Figure 2 and Figure S2). The most strongly
associated SNP, rs7072216, has alleles C/T at frequency 0.25/
0.75 in Europe (HapMap-CEU [29]). Our data indicate that
TMAu concentration and DMAp concentration both increase
with the number of copies of the major (T) allele. TMAu displays
non-additivity, with the T allele recessive, and the TT homozygote
class showing a greater-than-additive increase (on logarithmic
scale) on the levels of the other two genotypic classes (Figure 3).
There is a non-synonymous SNP—rs2147896—in strong LD with
rs7072216 (r2~1; see also Table S2A). Functional predictions
(SIFT [32] and PolyPhen [33]) and the PhyloP conservation score
[34–35] for rs2147896 did not point to a clear functional impact,
or to it being significantly conserved (Table S2B). SNP rs2147896
does not lie in a known protein domain, and web-based protein
structure-modelling tools [36–37] did not predict that the
rs2147896 polymorphism would have an effect on PYROXD2’s
ligand binding site. However, PYROXD2 (C10orf33) eQTLs have
been discovered in fibroblasts (rs2147897 [2]) and liver (rs2147901
[38]), with these eQTLs in high LD (up to r2~1:00 and r2~0:76
respectively) with mQTL SNPs of TMAu and DMAp (Table S3).
This raised the possibility that eQTL-driven population variation
Figure 3. Relative metabolite concentrations against genotypes at their most significantly associated mQTL SNP. Each point
corresponds to a study participant’s mQTL genotype and corresponding metabolite concentration. Metabolite identifiers are labelled at top.
Genotypic classes for each mQTL are shown on the horizontal axis (random horizontal variation within each genotypic class is introduced for clarity);
dbSNP identifiers are labelled at bottom. At each metabolite peak, the transformed data vector shown in the plot is v~log2 w=min w fg ðÞ , where
w denotes the vector of normalized peak heights at that peak (prior to any logarithmic transformation, as described in Materials and Methods). So, the
transformation maps to zero the lowest observed concentration of each metabolite, and log2(fold change) can be visually quantified relative to this
baseline level. In particular, the maximum observed log2(fold change) in a metabolite’s concentration is easily accessible from the plot. Within-
participant replicate observations (biological and technical) were averaged on log2 scale.
doi:10.1371/journal.pgen.1002270.g003
Table 3. Statistical characterization of
1H NMR mQTL effects.
Discovery Stage
(MolTWIN) Replication Stage (MolOBB)
ID Beta
a S.E.
Beta
p-value Beta S.E.
Beta
p-value Replicated
b
TMAu -1.10 0.08 2.8E-23 -1.19 0.12 7.9E-15 *
N-ACu 1.06 0.09 4.1E-19 1.10 0.13 1.4E-11 *
BAIBu 1.54 0.21 5.9E-11 1.25 0.23 1.1E-06 *
DMAp -0.65 0.09 8.6E-11 -0.52 0.19 0.0081 *
aAdditive genetic effect with increasing number of copies of the minor allele
(minor/major alleles are shown in Table 1).
bSignificant at a level of 0.0125 (significance level of 0.05 adjusted for
conducting 4 tests by the Bonferroni method).
doi:10.1371/journal.pgen.1002270.t003
mQTLs Exhibit Genetic Evidence of Selection
PLoS Genetics | www.plosgenetics.org 6 September 2011 | Volume 7 | Issue 9 | e1002270in mRNA transcription at PYROXD2 mediates the mQTL of
TMAu and DMAp.
Inordertoinvestigate thiseQTLhypothesis further,weextracted
estimates of PYROXD2 mRNA abundance from two separate gene-
expression microarray data sets measured on abdominal subcuta-
neous adipose tissue and whole-blood samples from the MolTWIN
cohort (Materials and Methods). We found that PYROXD2 was
expressed in whole blood, but found no evidence of rs7072216
being an eQTL of PYROXD2 in whole blood (p~0:61), a finding
consistent with [2], in which PYROXD2 eQTLs were neither
discovered in T cells nor in lymphoblastoid cell lines. However, we
did find rs7072216 to be an eQTL of PYROXD2 in subcutaneous
abdominal adipose tissue (p~1:3|10{15), with gene expression
decreasing in the number of copies of the T allele. We plotted the
mutual dependence between rs7072216 genotype, PYROXD2 gene
expression in adipose tissue, and TMAu concentration (Figure 6).
TMAu concentration was strongly negatively correlated with
PYROXD2 expression (Pearson’s r~{0:66, p~1:4|10{18).
We examined these particular gene expression data (i.e. measured
in fat and blood cells) because they had been acquired already on
MolTWIN cohort members. In performing this analysis, we were not
suggesting that variation in gene expression in fat has a direct impact
on the concentration of TMAu or DMAp. However, a substantive
proportion of eQTLs modulate expression in a similar way in
different tissues [39]. Thus, in identifying and characterizing the
mutual dependence of TMAu concentration, rs7072216 genotype,
and PYROXD2 expression in a mechanistically unrelated tissue (i.e.
fat), we have raised the possibility that a qualitatively similar
relationship with PYROXD2 expression will be observed in the tissue
that truly mediates the mQTL effect (likely to be liver or kidney).
Analysis of BAIBu mQTL (
1H NMR)
The SNPs that are significantly associated with BAIBu map to
chromosome 5p13.2 within AGXT2 (alanine-glyoxylate amino-
transferase 2). AGXT2 is known to be expressed in human liver
and kidney. An eQTL for AGXT2 was reported in liver ([38] and
Table S3), but this eQTL is not in LD with the mQTL SNPs
(r2ƒ0:06), and so does not explain the BAIBu mQTL.
Two of the most significant mQTL SNPs for BAIBu were
rs37369 (T/C at 0.09/0.91) and rs37370 (C/T at 0.08/0.92), with
r2~0:74 (HapMap-CEU [29]) between the two SNPs (Table
S2A). At SNP rs37370, one of the MZ twin pairs in the study was
homozygous for the minor C allele; these subjects had higher
BAIBu concentration than those in the other genotypic classes.
Each of rs37369 and rs37370 is a non-synonymous, missense
coding mutation in AGXT2, leading to an amino acid substitution
in AGXT2. At rs37369, the base change C619T leads to the
valine-to-isoleucine substitution V140I. At rs37370, T506C leads
to the asparagine-to-serine substitution N102S. At each SNP, the
concentration of BAIBu increased in the number of copies of the
minor allele. Both SNPs lie in the pyridoxal phosphate-dependent
transferase major domain (IPR015424) with rs37369 in subdo-
main 1, and rs37370 in subdomain 2. We extracted functional
predictions (SIFT [32] and PolyPhen [33]) and PhyloP conserva-
tion scores [34–35] for rs37369 and rs37370, but discovered no
substantive evidence in favour of functional impact or of either
SNP being significantly conserved (Table S2B). We used the web
servers Phyre2 [36] and 3DLigandSite [37] to predict AGXT2
protein structure and to investigate whether rs37369 and rs37370
were likely to affect AGXT2’s predicted ligand binding site, but
neither SNP was identified in these analyses as having an impact
on the binding site.
Replication of Illig et al. (Biocrates)
We analysed the 15 mQTL associations reported in Illig et al.
[14] using SNP genotypes and Biocrates-platform data from the
MolOBB and MolTWIN cohorts (having removed individuals
overlapping with the TwinsUK cohort used in [14]). We replicated
Figure 4. Biological variance decomposition for metabolic traits driven by mQTLs featuring in the current paper. Results from the
current paper’s replication of [14] on the Biocrates platform are shown in the bottom section of the plot. Results for
1H NMR mQTLs identified in the
current study are shown in the upper section. For each metabolic trait (labelled right), the plot displays estimates of the proportion of biological
variance explained by five complementary sources (labelled top; see Materials and Methods for explanation), including the mQTL SNP genotypes,
familial variation excluding the mQTL SNP variation, individual environmental variation, and two types of visit variation (individual and common).
Posterior distributions for proportions are represented as follows: the central tick in a box marks the posterior mean, the ends of a box mark the
posterior quartiles, and the whiskers represent a 95% credible interval (extending to the 2.5 and 97.5 posterior percentiles).
doi:10.1371/journal.pgen.1002270.g004
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replicated beyond the nine replicated by Illig et al. themselves (so
that now a total of 13 of the 15 mQTLs identified in [14] have
been replicated). The same significance level was used as in the
replication section of [14], specifically a level of 0.05 adjusted by
the Bonferroni method to account for 15 tests being performed
(i.e. an adjusted significance level of 0.0033).
Discussion
The current paper has extended recent studies [14,19] in
investigating the genetic basis of human metabolism. We analysed
plasma and urine samples using
1H NMR, whilst Illig et al. [14]
analysed serum samples using the Biocrates platform (targeted
metabolomics using FIA-MS) [18]. While our examination of
urine metabolites did not overlap with previous work, there was
some minimal overlap between the metabolites targeted in blood
(plasma or serum) by Biocrates and
1H NMR [40]. The Biocrates
platform focuses specifically on a pre-selected set of amino acids
and lipids [14,18]. In contrast,
1H NMR spectroscopy is
untargeted, quantifying the most abundant 50–100 metabolites
in a biofluid, typically those above 10 micromolar in concentration
[15]. We were able to annotate 38 metabolites in our plasma
1H
NMR data, of which five were also targeted by the Biocrates
platform (glutamine, glycine, leucine, tyrosine and valine). So, the
sets of metabolites considered by the two studies are minimally
overlapping and therefore complementary.
The MolTWIN plasma and urine samples were collected
longitudinally from twins, and analysed with technical replication
using
1H NMR and the Biocrates platform. This study design
permitted a detailed decomposition of population variance in
metabolite concentration (Figure 4 and Table 4). We estimated the
proportion of biological variation in metabolite concentration
explained by the corresponding mQTL SNP (biological variation
included all phenotypic variation apart from that which was
experimentally derived). For the newly discovered
1H NMR
mQTLs, this proportion varied between 40%–64%. For the 13
currently replicated mQTLs discovered by Illig et al. [14], the
proportion varied between 2%–35%. This discrepancy is ex-
plained by the different study designs, and mainly by the different
sample sizes (Figure 5).
The current study’s twin design allowed us to quantify the
proportion of biological variance in metabolite concentration that
was attributable to familial factors (i.e. genetic and common-
environmental effects). For Illig et al.’s replicated mQTLs, the
‘non-SNP’ familial variation (i.e. familial variation not explained
by the mQTL) was considerable, explaining on average 44%
(range 9%–70%) of biological variation in the corresponding
metabolic trait (Figure 4 and Table 4). On average, Illig et al.’s
mQTL SNPs explained 25% (range 5%–82%) of the total familial
variation in the corresponding metabolic traits. So, other genetic
and common-environmental factors had substantial influence in
addition to (and perhaps interacting with) the effects of the
mQTLs themselves.
Table 4. Decomposition of biological population variation in metabolic traits.
Percentage of Biological Variance Explained
a
Platform Biofluid Metabolic Trait
b SNP mQTL SNP Familiality
c Indiv. Envir.
d Indiv. Visit
e
Common
Visit
1H NMR Urine TMAu rs7072216 64% (55–72) 15% (5–24) 2% (0–8) 16% (10–23) 4% (0–10)
1H NMR Urine N-ACu rs9309473 53% (42–62) 14% (4–25) 3% (0–12) 28% (19–38) 3% (0–11)
1H NMR Urine BAIBu rs37369 40% (27–53) 44% (32–57) 1% (0–4) 8% (5–12) 7% (2–13)
1H NMR Plasma DMAp rs6584194 40% (23–57) 22% (3–46) 14% (0–36) 11% (0–34) 13% (0–36)
Biocrates Plasma PC aa C36:3/PC aa C36:4 rs174547 35% (23–46) 12% (1–25) 22% (9–37) 26% (15–40) 5% (0–15)
Biocrates Plasma C3/C4 rs2014355 29% (16–40) 51% (37–65) 5% (0–15) 14% (7–23) 1% (0–7)
Biocrates Plasma C12/C10 rs211718 15% (5–27) 62% (47–76) 5% (0–15) 14% (6–24) 4% (0–14)
Biocrates Plasma C9/C10:2 rs2286963 22% (10–35) 26% (5–45) 9% (0–27) 38% (21-56) 5% (0–22)
Biocrates Plasma PC aa C40:3/PC aa C42:5 rs9393903 12% (3–24) 32% (6–55) 41% (19–65) 10% (0–25) 6% (0–20)
Biocrates Plasma Gly–PTC/PC ae C38:2 rs2216405 13% (4–24) 32% (10–52) 22% (4–45) 28% (15–47) 4% (0–16)
Biocrates Plasma PC ae C32:1/PC ae C34:1 rs7156144 7% (1–17) 27% (5–49) 13% (0–36) 42% (20–65) 11% (0–33)
Biocrates Plasma PC ae C38:1/PC aa C28:1 rs11158519 7% (1–16) 66% (51–79) 22% (11–37) 3% (0–8) 1% (0–4)
Biocrates Plasma SM (OH) C24:1/SM C16:0 rs168622 7% (0–17) 44% (22–64) 28% (9–51) 19% (3–38) 2% (0–12)
Biocrates Plasma C14:1-OH/C10 rs8396 2% (0–9) 74% (52–90) 5% (0–18) 16% (1–33) 3% (0–16)
Biocrates Plasma C0 rs7094971 9% (2–17) 41% (23–58) 8% (0–24) 39% (25–57) 3% (0–14)
Biocrates Plasma PC ae C44:5/PC ae C42:5 rs2046813 8% (1–19) 61% (41–76) 18% (6–35) 11% (4–20) 2% (0–8)
Biocrates Plasma C14/C16:1 rs603424 9% (1–20) 47% (14–73) 14% (0–42) 21% (0–48) 10% (0–34)
Biocrates Plasma Val-PTC/C5 rs272889 9% (2–19) 40% (18–58) 7% (0–26) 40% (25–58) 3% (0–17)
Biocrates Plasma Orn-PTC/Ser-PTC rs541503 2% (0–7) 44% (15–68) 30% (7–56) 13% (0–36) 12% (0–32)
aSee Materials and Methods for the definition of each component of variance. Posterior mean estimates are shown with parenthesized central 95% posterior credible
intervals.
bSupplementary material of [14] has details of the metabolites targeted by the Biocrates platform, and their abbreviations.
cVariation attributable to familial (i.e. heritable and common-environmental) sources, but not to the mQTL SNP itself.
dIndividual environment.
eIndividual visit.
doi:10.1371/journal.pgen.1002270.t004
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variation in all common
1H NMR-detectable urine and plasma
metabolites, using the MolTWIN
1H NMR data of the current
study, though without incorporation of the genotype data. We
decomposed biological population variation into components,
including that explained by familial sources and that explained by
longitudinally stable sources. On average (across
1H NMR peaks),
familial sources explained 42% (IQR 32-52) of variation in plasma
metabolite concentrations and 30% (IQR 17-39) of variation in
urine ones. Longitudinally stable sources explained 60% (IQR 51-
72) of variation in plasma metabolite concentrations and 47%
(IQR 35-60) of variation in urine ones. The substantive
widespread presence of familial and stable variation across the
urine and plasma
1H NMR metabolomes has implications for the
design and interpretation of metabolite biomarker-discovery
studies [41].
Interestingly, two of the
1H NMR mQTLs (discussed in detail
below) have experienced recent positive selection in European
populations [8]. The fact that these mQTL SNPs experienced
selection suggests that molecular and phenotypic perturbations
downstream of them may be biomedically interesting [31]. Also,
the identification of functional consequences of variation at these
loci strengthens the existing genetic evidence for selection having
acted at these loci [31]. The observed genetic signature of positive
selection suggests that an allele at the locus conferred a net
advantage, relative to other alleles, under some environmental
pressures, yet did not confer a net advantage under other
environmental pressures. Humans may still be exposed to relevant
environmental heterogeneity, and so the biomedical implications
of these loci may become most clear once gene-environment
interactions are incorporated into disease-susceptibility models. It
will be initially of interest to investigate how physiological
metabolite concentrations vary between world-wide populations
as a result of different mQTL allele frequencies and environmental
backgrounds. Metabolic profiles have the potential to reflect the
synergy of genetic and environmental influences, and can thus
provide unique insights into disease susceptibility at a population
level [42–43].
During the revision stage of the current paper, an article by
Suhre et al. [44] appeared, describing a GWAS of urine
metabolite concentrations targeted by the
1H NMR-based
Chenomx platform. Only one of the three mQTLs identified in
the current paper—that of BAIBu—was identified in [44] (see
further discussion of the BAIBu mQTL in the dedicated section
below). A comparison of the current study with [44] illustrates
nicely some of the differences between targeted and untargeted
assays. In the current study we searched for strong genetic drivers
of the comprehensive set of common urine and plasma metabolites
detectable by
1H NMR. In contrast, Suhre et al. investigated
genetic drivers of a targeted subset of the urine
1H NMR
Figure 5. Relationship between sample size and the size of effect detectable with 80% power in each study (shown by solid lines).
The effect size is parameterized by r2, which is the proportion of total population variance in metabolite concentration explained by the mQTL
genotype (or, equivalently, the squared correlation between genotype and trait). It is assumed that the family-wise error rate in each study is
controlled at 0.05 using the Bonferroni method. The number of tests performed is calculated as the product of the SNP and metabolite counts, as
shown in the legend. Dashed lines relate the actual sample size of each study to that study’s detectable effect size.
doi:10.1371/journal.pgen.1002270.g005
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the current study, and thus had statistical power to detect relatively
weak genetic effects. The untargeted nature of the current study
allowed the detection of two strong mQTL drivers of urine
metabolite concentrations—TMAu and N-ACu—that were not
targeted by the Chenomx platform used in [44]. A disadvantage of
our untargeted approach in this context was that peaks had to be
annotated with their corresponding metabolite. In the current
study we were unable to attribute N-ACu to a single metabolite,
and so the N-ACu mQTL was reported as driving concentrations
of one or more N-acetylated compounds (X.NH.CO.CH3, with X
unknown). Also, the unambiguous annotation of BAIBu was
assisted by input from Suhre et al. [44], previous to which we had
annotated the peak non-uniquely as CH3.CH.Y, with Y unknown
but containing CH or CH2 and an electronegative substituent.
Discussion of TMAu and DMAp mQTL (
1H NMR)
Genetic variation at PYROXD2 has experienced recent positive
selection in European populations [8], with the T allele of
rs7072216 at frequency 0.75 in Europe (HapMap-CEU), and at
0.14 in Africa (HapMap 3 individuals from Yoruba in Ibadan,
Nigeria, Africa, i.e. HapMap-YRI [29]). The haplotype that was
relatively advantageous in European populations is associated with
decreased expression of PYROXD2 and increased concentration of
TMAu and DMAp. Further work will be necessary to clarify the
mechanisms linking: DMAp and TMAu levels; PYROXD2 gene
expression; and genetic variation in LD with rs7072216 (such as
the non-synonymous SNP, rs2147896). The signature of selection
at PYROXD2 is indirectly suggestive of biomedical relevance; we
also note that the set of genes showing evidence for positive
selection is enriched for genes involved in oxidoreductase activity
[8].
There have been a number of studies that have examined the
sources of variation in physiological concentrations of methyl-
amines and their derivatives, e.g. [45–46]. The current paper
sheds light on this field from a new genetic angle, and it will be
useful to integrate the mQTL effects into known pathways. Gut
microbiota play an important role in the formation of methyl-
amines from dietary sources in mammals—they create TMA from
choline, and convert TMA into DMA [45–46]. Trimethylamine
N-oxide (TMAO) is formed endogenously in the liver via the N-
oxygenation of TMA by the flavin-containing monooxygenase
(FMO) protein family, and particularly by FMO3 [47]. Gut
microbial activity has been linked to disease through physiological
levels of DMA, TMA and TMAO [48–49].
It may prove productive to relate the TMAu mQTL finding to
the rare recessive genetic disorder trimethylaminuria, in which
mutations at FMO3 disrupt conversion of TMA to TMAO,
resulting in high physiological levels of TMA and an accompa-
nying fish-odour phenotype [47]. Trimethylaminuria cases exhibit
relatively low values of the ratio TMAOu/(TMAOu + TMAu),
Figure 6. TMAu’s mQTL effect may be mediated by variation in mRNA transcription at PYROXD2. Each point represents, for a single study
participant, their concentration of TMAu (vertical axis), their expression of PYROXD2 in adipose tissue (horizontal axis), and their mQTL genotype
(point colour). The intensity data, w, on each of the vertical and horizontal axes have been transformed v~log2 w=min w fg ðÞ . This transformation sets
the minimum observation to zero on log2 scale, and presents log2(fold change) relative to the minimum value.
doi:10.1371/journal.pgen.1002270.g006
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the current study have values of this ratio that are within the range
typical of trimethylaminuria controls (Figure S6 and [50]). It will
be interesting to investigate the effect, if any, of genetic variation at
the TMAu mQTL on TMA levels among trimethylaminuria
cases.
Discussion of N-ACu mQTL (
1H NMR)
The N-ACu mQTL lies within a large 500 kb haplotype block
(Figure 1), and there are a number of genes (and eQTLs, Table S3)
in LD with it. Of these genes, NAT8 is a likely candidate for
mediating the association between SNP variation and N-ACu
(urine concentration of N-acetylated compound(s)), since NAT8’s
encoded enzyme specifically catalyzes N-acetylation—NAT8’s
enzyme is cysteinyl-conjugate N-acetyltransferase, CCNAT [51].
We relate our N-ACu mQTL finding to other research that has
shown: (i) that the region harbours SNPs associated with renal
function [22–23,52]; and (ii) that the region has been the site of
positive selection on standing genetic variation [8,30].
Two recent renal-function GWASs identified rs13538 as a
clinically associated SNP [22–23,52] with the minor G allele
increasing susceptibility to renal dysfunction. Chambers et al. [22]
proposed that a non-synonymous mutation in NAT8 (the A595G
change at rs13538, producing a non-conservative amino acid change
F143S in CCNAT) reducesacetylation efficiency, thus leading to toxin-
induced kidney injury. The N-ACu mQTL SNP rs9309473 is in
strong LD (r2~1) with GWAS SNP rs13538 (both SNPs with alleles
A/G at frequency 0.79/0.21 in HapMap-CEU [29]). We found the
non-synonymous mutant allele (G) at rs13538 to be associated with
increased levels of N-ACu. Thus, whilst our findings provide evidence
of differential acetylation efficiency driven by genetic variation in LD
with rs13538, their directionality is not consistent with the specific
mode of action proposed in [22]. Furthermore, a recent functional
study [51] found enzymatic activity of mutant (F143S) CCNAT to be
comparable to that ofthe wild-typeprotein(andsoisalsoinconsistent
with the mode of action proposed in [22]).
Scheinfeldt et al. [30] studied the signature of selection in this
region, specifically examining two complementary sets of haplo-
types: the ‘‘ancestral’’ and ‘‘derived’’ haplogroups (HapA/HapD
respectively, at frequency 0.26/0.74 in the HapMap-CEU
European population, but at 0.89/0.11 in the HapMap-YRI
African population [29]). It has been proposed that positive
selection drove up the frequency of HapD (relative to HapA) in
Eurasian populations about 15,000 years ago [30]. The N-ACu
mQTL SNP rs9309473 is in strong LD with HapA/HapD status
(r2~0:96 in HapMap-CEU, with alleles G/A of rs9309473 highly
predictive of HapA/HapD status respectively). An increasing
number of copies of HapA is associated with increased urine
concentration of N-acetylated compound(s) (N-ACu), and with
increased susceptibility to renal dysfunction [22–23].
Discussion of BAIBu mQTL (
1H NMR)
The BAIBu mQTL wasalso identifiedbySuhre et al. [44], where
they noted the following. Elevated levels of BAIBu had been shown
through family studies to be autosomal recessive [53], but the causal
locus had been previously unknown. The association of a SNP in
AGXT2 with BAIBu levels is consistent with the role of AGXT2’s
encoded enzyme, mitochondrial aminotransferase, which is ex-
pressed primarily in the kidney and catalyzes the reaction of BAIB
with pyruvate to form 2-methyl-3-oxopropanoate and alanine (EC
Table 5. Summary of the current study’s replication of Illig et al.’s [14] mQTL associations (Biocrates platform).
Illig et al.
a Current Paper Replicated
b
SNP Gene Chr Position
c
Ref./
Alt.
d MAF
e Metabolic Trait
f Beta
g p-value Beta p-value
Illig
et al.
h
Current
Paper
rs174547 FADS1 11 61327359 T/C 0.304 PC aa C36:3/PC aa C36:4 0.151 6.5E-179 0.161 1.3E-20 * *
rs2014355 ACADS 12 119659907 T/C 0.277 C3/C4 20.218 5.1E-96 20.254 5.7E-13 * *
rs211718 ACADM 1 75879263 C/T 0.305 C12/C10 0.12 1.3E-63 0.098 3.7E-06 * *
rs2286963 ACADL 2 210768295 T/G 0.365 C9/C10:2 0.219 3.1E-60 0.169 4.1E-06 * *
rs9393903 ELOVL2 6 11150895 G/A 0.246 PC aa C40:3/PC aa C42:5 0.087 2.3E-42 0.072 9.9E-05 * *
rs2216405 CPS1 2 211325139 A/G 0.185 Gly-PTC/PC ae C38:2 0.129 1.9E-30 0.224 2.0E-06 *
rs7156144 PLEKHH1 14 67049466 G/A 0.414 PC ae C32:1/PC ae C34:1 20.042 1.7E-28 -0.037 5.0E-04 * *
rs11158519 SYNE2 14 63434338 G/A 0.145 PC ae C38:1/PC aa C28:1 20.083 1.5E-27 -0.094 7.7E-05 *
rs168622 SPTLC3 20 12914089 G/T 0.375 SM (OH) C24:1/SM C16:0 0.061 5.2E-26 0.045 2.0E-03 * *
rs8396 ETFDH 4 159850267 T/C 0.298 C14:1-OH/C10 0.102 3.5E-24 0.066 3.9E-02 *
rs7094971 SLC16A9 10 61119570 A/G 0.135 C0 20.091 3.8E-20 20.104 3.0E-05 * *
rs2046813 ACSL1 4 186006153 T/C 0.322 PC ae C44:5/PC ae C42:5 0.033 3.6E-18 0.042 2.7E-03 *
rs603424 SCD 10 102065469 G/A 0.194 C14/C16:1 0.054 1.5E-17 0.053 1.1E-02
rs272889 SLC22A4 5 131693277 G/A 0.385 Val-PTC/C5 20.075 7.9E-16 -0.102 2.5E-04 *
rs541503 PHGDH 1 120009820 T/C 0.379 Orn-PTC/Ser-PTC 0.058 3.0E-12 0.039 2.2E-01
aEstimate and p-value from the discovery stage of [14] (their KORA cohort).
bSignificant at a level of 0.0033 (significance level of 0.05 adjusted for conducting 15 tests by the Bonferroni method).
cNCBI build 37 coordinates.
dReference/alternative Allele.
eMinor allele frequency, from Table 1 of [14].
fSupplementary material of [14] has details of the metabolites targeted by the Biocrates platform, and their abbreviations.
gBeta is the estimate of the additive effect of one copy of the reference allele, normalized by the mean of the metabolic trait.
hSignificant in the replication stage of [14] (their TwinsUK cohort); see Table 1 of [14] for details.
doi:10.1371/journal.pgen.1002270.t005
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homeostasis might contribute to hyper-b-amino-isobutyric aciduria,
a relatively common Mendelian metabolic disorder in humans [54].
Suhre et al. [44] proposed rs37369 as a likely candidate for the
causative SNP driving both variation in BAIBu concentration and
susceptibility to hyper-b-amino-isobutyric aciduria.
We found the non-synonymous SNP rs37369 (p~5:9|10{11)
to be marginally more significantly associated with BAIBu
concentration than the other non-synonymous SNP, rs37370
(p~6:1|10{10). This mildly supports rs37369 as the causal SNP
driving BAIBu levels, relative to rs37370, though the true causal
genetic polymorphism may be neither of these SNPs, but instead
variation in strong LD with them. We used existing tools to predict
the effect of rs37369 and rs37370 polymorphism on AGXT2
function (see Results), but this analysis did not reveal any clear
functional consequences of these non-synonymous polymor-
phisms. Further work will be necessary to characterize with
certainty the causal link between genetic variation at the AGXT2
locus and BAIBu concentration.
Conclusion
In conclusion, we have designed and conducted an mQTL
study of plasma and urine metabolites detectable by
1H NMR. We
discovered and replicated four novel metabolite-SNP associations,
with each SNP explaining 40% or more of biological variation in
metabolite concentrations. The mQTLs that we discovered have
interesting properties: two of the three mQTL regions have
experienced recent positive selection in European populations; one
mQTL is in strong LD with a SNP identified in a kidney-function
GWAS. Our findings pave the way forward for investigating the
potential biomedical relevance of these regions.
Materials and Methods
Ethics statement
The MolTWIN study was approved by St. Thomas’ Hospital
Research Ethics Committee (EC04/015 Twins UK). The
MolOBB study received ethical approval from Oxfordshire REC
C (08/H0606/107).
Participant recruitment—MolTWIN
The 142 participants in the current study were recruited from
the UK Adult Twin registry at St. Thomas’ Hospital (www.
twinsUK.ac.uk): a longitudinal epidemiological study of 11,000
twins (mostly female), for which extensive clinical, anthropometric,
lifestyle, and demographic information, and a wide range of
biological measurements have been collected [55]. Eligible
volunteers were healthy, Caucasian, post-menopausal females of
Northern European descent, between 45–76 years of age. Eligible
twins were sent an information sheet containing details of the
study, and two consent forms. After each twin had returned a
completed consent form, she was contacted by letter and phone to
book her appointment. The composition of the cohort was: 51 MZ
pairs, 19 DZ pairs, and two unrelated individuals.
In the MolTWIN cohort, 33 of the MZ twin pairs donated
samples twice; the median inter-visit time across all such pairs was
118 days (IQR: 96-134). Both twins in a pair always visited on the
same day, and each visit was scheduled at either 10:00 or 14:00
(with repeated visits of each individual not necessarily scheduled at
the same time of day).
Participant recruitment—MolOBB
The 69 participants in the current study were selected from the
Oxford Biobank [20] (OBB). Specific OBB cohort members were
selected on the basis of case/control status for metabolic syndrome
according to International Diabetes Foundation Criteria [56]. The
set of subjects comprised 42 controls (17 female, 25 male), and 27
cases (12 female, 15 male).
Sample collection
Fasting blood and urine samples were collected at all clinic visits
of each participant. Spot urine samples were centrifuged (16060 6
g) at 4uC for 10 min before being stored at 280uC. Fresh blood
was collected in a 9 mL tube through venepuncture. Samples for
1H NMR analysis were collected in heparin tubes, whilst samples
for Biocrates-platform analysis were collected in EDTA tubes.
Blood samples were kept on ice for 20 min prior to centrifugation
(16060 6g) at 4uC for 10 min, and subsequent storage at 280uC.
Genotyping, quality control, and imputation (MolTWIN
and MolOBB)
DNA was extracted from whole-blood samples using Gene-
Catcher (Invitrogen Life Technologies, Carlsbad, USA) according
to manufacturer’s protocol. Genome-wide SNP genotypes were
measured on a total of 166 individuals: 70 from the MolOBB
cohort, and 96 from the MolTWIN cohort (one MZ twin from
each MZ pair was genotyped, whilst both members of each DZ
twin pair were genotyped). The genotyping assay used was the
Illumina 317K BeadChip SNP array (Illumina, San Diego, USA).
Quality control on the genotyped subjects was performed in a
way similar to those described previously by the Wellcome Trust
Case Control Consortium [57]. Two MolTWIN samples were
removed due to sample genotyping success rate , 95% and three
samples (two from MolTWIN, one from MolOBB) were removed
due to non-European ancestry (note that the cohort compositions
given in the Participant Recruitment sections are after quality
control). SNPs were removed (i) if MAF , 1%, or (ii) if genotyping
success rate ,95% and MAF . 5%, or (iii) if genotyping success
rate ,99% and MAF , 5%. Hardy-Weinberg equilibrium
(HWE) was calculated by combining all unrelateds of the MolOBB
and MolTWIN data sets (i.e. one twin per twin pair) and the
hypothesis of HWE was tested at a significance level of 10
24; SNPs
at which HWE was rejected were omitted from the study. After
quality control, the genotypes of ungenotyped MZ twins were
copied from their corresponding genotyped twin. The final data
set prior to imputation comprised 69 MolOBB members and 142
MolTWIN members genotyped at 296,017 autosomal SNPs.
Measured genotypes were used to impute an additional
2,245,627 SNPs using the HapMap-CEU population (release 22)
as reference [29]. The imputations were performed using
IMPUTE [58]. We included SNPs in our analysis only if the
imputation quality score was greater than 0.4. As output for a
single SNP in an individual, IMPUTE provided probabilities of
the individual having each of three possible genotypes (zero, one,
or two copies of the reference allele). Prior to incorporating
imputed genotypes into the statistical models, we preprocessed
them, estimating the true genotype by that which was allocated
highest probability by IMPUTE. Including both typed and
imputed SNPs, we used a total of 2,541,644 autosomal SNPs for
association analysis.
Sample preparation, data acquisition, and preprocessing
(MolTWIN gene-expression data)
Total RNA was extracted from adipose tissue biopsies with
TRIreagent (SIGMA-ALDRICH, Gillingham, UK) and quantified
using a NanoDrop. For whole-blood samples, PAXgene tubes were
used, and RNA was extracted according to the manufacturer’s
mQTLs Exhibit Genetic Evidence of Selection
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MessageAmp II 96-well amplification kit (Applied Biosystems, CA,
USA). Labelled RNA was hybridized onto Affymetrix HGU133
Plus2 arrays, washed, stained, and scanned for fluorescence intensity
according to manufacturers protocols (Affymetrix, Inc., USA).
Data were preprocessed using the RMA method without
background correction (i.e. quantile normalization followed by
robust probe-set summarization) [59]. Whole-blood array data
were preprocessed separately from adipose-tissue array data.
Publicly available custom chip-definition files (CDFs) were
downloaded (version 11) (http://brainarray.mbni.med.umich.edu
/Brainarray/Database/CustomCDF/CDF_download.asp) and used
to group probes into sets, each set corresponding to an Ensembl-
annotated gene, resulting in 18,394 such genes represented in the
array data. See [60] for a description of how these CDFs were
created, along with a comparison of their properties with the
CDFs produced by Affymetrix.
Expression data were extracted at the PYROXD2 gene, and used
in the current paper’s analysis of the mQTL for TMAu and
DMAp.
Sample preparation and data acquisition (Biocrates)
EDTA plasma samples were vortexed after thawing and
centrifuged at 4uC for 5 min at 10,000 x g prior to loading of
10 mL of supernatants onto the 96-well kit plate. Processing of the
AbsoluteIDQ kit followed the protocol specified by the manufac-
turer, including the following automated steps on the Hamilton
ML Star robotics platform (Hamilton Bonaduz AG, Bonaduz,
Switzerland): (i) drying plasma samples under a nitrogen stream,
(ii) derivatization of amino acids with 5% phenylisothiocyanate
reagent (20 mL), (iii) drying of samples, (iv) extraction of
metabolites and kit internal standards with mM ammonium
acetate in methanol (300 mL), (v) centrifugation through filter
plate (2 min, 500 x g), vi) dilution with 600 mL MS running
solvent. 20 mL of the final extracts were applied to flow injection
analysis mass spectrometry.
Samples were analyzed using an API 4000 triple quadrupole
mass spectrometer (ABSciex) equipped with an Agilent 1200 Series
HPLC and a HTC PAL auto sampler from CTC controlled by the
software Analyst 1.5. The standard flow injection method
comprising two 20 mL injections (one for positive and one for
negative electrospray ionisation mode) was applied for all
measurements. Quantification was achieved by multiple reaction
monitoring detection in combination with the use of stable isotope-
labelled and other internal standards [61]. Data evaluation for
quantification of metabolite concentrations was performed with
the MetIQ software package (integral part of the AbsoluteIDQ
kit). Concentrations of all metabolites are initially calculated in
mM. The method has been proven to conform to FDA-Guidelines
[62], which imply proof of reproducibility within a given error
range. Analytical specifications for detection limit (LOD) and
evaluated quantification ranges, further LOD for semi-quantita-
tive measurements, identities of quantitative and semi-quantitative
metabolites, specificity, potential interferences, linearity, precision
and accuracy, reproducibility and stability were described in
Biocrates manual AS-P150. The LODs were set to three times the
values of zero samples. The lower and upper limits of
quantification were determined experimentally by Biocrates AG
(Innsbruck, Austria). In addition, the technical variability of the
Biocrates platform had been quantified previously by Illig et al.
[14]. Their Supplementary Table 4 displayed the coefficient of
variation, CV, for each of 163 metabolite concentrations assayed
in [14], and measured under the same conditions on the same
platform in the current study. The median CV across metabolites
was 7.4% (IQR: 6.1%-12.4%) [14], which demonstrated a useful
degree of precision for the majority of metabolites.
We performed quality-control checks, including boxplots and
principal-component score plots, on the Biocrates-platform data to
identify failed assays, where an assay refers to the measurement of
163 metabolite concentrations in a biological sample. Of a total of
356 assays across the MolOBB and MolTWIN cohorts, we
identified two assays that exhibited anomalously low concentra-
tions of all metabolites (relative to the levels observed in the other
assays); we omitted those two assays from further analysis.
Sample preparation and data acquisition (
1H NMR)
Thawed samples were centrifuged at 16060 6 g for 10 min.
Samples were aliquotted into two technical replicates prior to
samplepreparation.Plasmawasdiluted1 in4 inphysiologicalsaline
prepared in 20% D2O supplemented with 0.1% (w/v) sodium azide
asa bacteriostaticagent and1.5 mMsodiumformate as a chemical-
shift reference (d8.452). Urine was diluted 2 in 1 in phosphate buffer
(20% D2O, pH 7.4) supplemented with 1 mM trimethylsilyl-
2,2,3,3-tetradeuteropropionic acid (TSP; d0.00) and 0.1% (w/v)
sodium azide. Sample aliquots were allocated to 96-well plates (and
wells thereon) in a randomized design.
Each experiment was acquired on a Bruker DRX 600 MHz
spectrometer (Rheinstetten, Germany) operating at 600 MHz (for
1H) using a 5 mm TXI flow-injection probe equipped with a z-
gradient coil, at 300 K, at a spectral width of 12019 Hz, with 96
transients being collected with 8 dummy scans using 64k time
domain data points. For both plasma and urine samples a standard
1D spectrum [RD290u23 ms290u2tm290u2acquire] with se-
lective irradiation of the water resonance during the relaxation
delay (RD, 2 s) and during the mixing time (tm, 0.1 s) was acquired.
Additionally, for the plasma samples, a spin-echo (Carr-Purcell-
Meiboom-Gill) spectrum [RD290u2(t/22180u2t/2)n2acquire]
with a total echo time of 608 ms (n=304, t=2000 ms) and a
diffusion-edited spectrum made using a bipolar pulse-pair
longitudinal eddy current delay pulse sequence with spoil gradients
immediately following the 90u pulses after the bipolar gradient
pulse pairs were acquired. Continuous wave irradiation was
applied during the relaxation delay at the frequency of the water
(or HOD) resonance. Eddy current recovery time (Te) was 5 ms,
and the time interval between the bipolar gradients (|) was 0.5 ms.
Further details may be found in [15,26,63].
Data preprocessing and feature extraction (
1H NMR)
Each of four data sets was passed independently through a semi-
automated preprocessing pipeline: phasing, alignment, denoising,
baseline correction, manual bin selection, normalization, quality
control, peak extraction, and logarithmic transformation.
Spectra were phased using in-house software (NMRProc,
T.M.D Ebbels and H.C. Keun, Imperial College London). All
other data analysis was performed in R [64]. Spectra were zero-
filled to 2
16 points. Urine spectra were aligned to TSP, set at
d0.00; plasma spectra were aligned to formate, set at d8.452 (peak
centres were defined by the position of the local maximum).
The spectra were denoised in the frequency domain using
wavelet-based methodology (a method similar to that described in
[65]). For baseline correction, we initially fitted a constant baseline
to each spectrum; however, visual inspection revealed that, for a
number of spectra, the fit was better on one side of the water peak
than on the other; natural variations in ionic strength resulting in
altered phase of the residual water resonance may contribute to
such an effect. Hence, a two-piece piecewise-constant baseline was
fitted to and subtracted from each spectrum; specifically, the
baseline on each side of the water peak was estimated by the 5th
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robust estimator of baseline location).
We plotted each peak; for those peaks that visually displayed
consistent presence across spectra, we manually created a bin and
used the bin to extract the peak’s data across all spectra. The
datum extracted from a bin in a spectrum was the intensity of the
highest local maximum (i.e. we used peak height as a proxy for
peak area), or was coded as a missing value if no local maximum
was present. We chose peak height to be the estimator of
concentration as, in addition to its simplicity, it had relatively good
robustness properties in the context of spectral artefacts (e.g. when
a peak’s location varied across spectra, or when neighbouring
peaks overlapped within spectra). If the width (at half height) of a
peak varies substantially across spectra, then peak height may be
less precise than area at quantifying concentration. Plots of peaks
did not reveal substantial peak-width variation in our data sets.
Only common peaks—present in at least 80% of spectra in their
corresponding data set—were included in downstream statistical
analysis, and only a peak’s non-missing data were included at the
statistical modelling stage. A missing datum, corresponding to
there being no local maximum in the peak’s ppm interval, typically
occurred for one of two reasons: (a) the corresponding metabolite’s
concentration was too low to create a local maximum, or (b) a
relatively large neighbouring peak overlapped the peak of interest
(i.e. the missing concentration is censored, but not necessarily low).
The omission of type (a) missing values from the analysis
potentially decreased statistical power to detect mQTLs driving
metabolite concentration variation at levels near or below the level
of detection. The omission of type (b) missing values from the
analysis increased the robustness of inference (and conserved
power) in the face of artefactual effects of overlapping peaks. To
illustrate, in Figure S7 we plotted the seven spectra (out of 432)
with missing values for DMAp, and the four spectra (out of 432)
with missing values for N-ACu. (There were no missing values for
TMAu and BAIBu.) At the DMAp peak, missing data were
representative of relatively low concentrations, approximately
within the lowest quartile of observed concentrations (so we may
have lost a small amount of power through missing-data handling).
For N-ACu’s missing data, the relevant peak’s size was obscured
by signal from an overlapping peak (missing values did not
necessarily correspond to near-zero concentration).
Prior to model fitting, we discarded any peaks that wereannotated
to exogenous metabolites (of ibuprofen or acetaminophen), to a
spike-in compound (TSP in urine, formate in plasma), or to urea (the
areaof which is affectedby water peaksaturation irradiation through
chemical transfer of saturated protons). Across the three plasma data
sets, 104 peaks were annotated to glucose; we discarded all but one
representative glucose peak in each plasma data set.
The spectra were normalized using probabilistic quotient
normalization [66]. The normalization was performed using data
from the retained peaks only; spectra were normalized to a
reference spectrum comprising median peak heights; missing
values were excluded from the calculation of medians. After
quality control, urine spectra were available for 142 MolTWIN
participants and 67 MolOBB participants; plasma spectra were
available for 140 MolTWIN participants and 68 MolOBB
participants. A logarithmic transformation was applied to make
the peak height distributions more symmetric–the entire spectrum-
wide set of peak heights were collectively shifted and scaled to lie
between zero and 100 and then transformed x.log(1zx).
Genome-wide association scan (MolTWIN
1H NMR data)
We tested each metabolite peak in turn for association with
2,541,644 autosomal SNPs. For this stage we averaged and
transformed the peak data as follows: (i) we averaged each subject’s
metabolite peak data across all biological and technical replicates; (ii)
for robustness, we mapped the quantiles of the resulting inter-subject
distribution to the quantiles of a standard Gaussian distribution. We
denote the resulting data vector by y. Wefitted the following additive
genetic model by ordinary least-squares regression at each SNP:
yi~mzbgizei
where i indexed subject; gi[ 0,1,2 fg was the number of copies of the
referenceallelepossessed byindividuali;a n dei wastheresidualerror
term. At each SNP, we calculated the conventional t-statistic for the
testofthenullhypothesisb~0.Wethentookthemaximumabsolute
t-statisticobserved across allSNPs tested,and thisstatistic, T,w a st h e
test statistic used for testing the null hypothesis, H0:t h em e t a b o l i t e ’ s
concentration was not associated with variation at any SNP in the
genome-wide panel.
We characterized the (metabolite peak-specific) null distribution
of T by permutation. For each of 5,000 permutations, we
randomly reassigned the measured metabolite levels of each MZ
pair to a different MZ pair, and randomly reassigned the
measured metabolite levels of each DZ pair to a different DZ
pair, yielding y(p) for the pth permutation. Such a permutation
crucially preserved the existing covariance structure on y induced
by polygenic genetic relatedness (identity-by-descent sharing) and
common-environmental effects between twins, while breaking
down any existing associations between y and identity-by-state
variation at SNPs. For the pth permutation, we calculated
t-statistics as before, quantifying the additive genetic association
between y(p) and the genotypes at each SNP. We then calculated
the maximum absolute t-statistic across SNPs, yielding the pth
draw from the null distribution, T(p).
For each metabolite, we rejected H0 only if the observed test
statistic exceeded all 5,000 draws from its null distribution, i.e. if
TwT(max):max T(p) : p~1,:::,5000

. Such a procedure con-
strained (to be small) the family-wise error rate (FWER) for testing
a single metabolite against genome-wide SNP variation. Specifi-
cally, (0, 0.0007) was an exact 95% confidence interval for the
FWER, based on the observation that none of the 5,000 draws
from the null distribution of T exceeded the observed statistic [67].
We concluded that our testing procedure controlled the false-
positive probability for each metabolite’s entire genome-wide scan
to be less than 0.001.
H0 was rejected for six of the 526 metabolite peaks tested. These
six peaks redundantly represented four metabolites, listed in
Table 2. For each metabolite, we examined the subset of SNPs
that reached genome-wide significance (defined as those SNPs
whose t-statistics exceeded, in absolute value, the metabolite’s
maximum null test statistic, T(max); shown in Table S1). For each
metabolite, the set of genome-wide significant SNPs co-localized to
a single genomic region; we defined a metabolite’s hit region to be
the smallest contiguous region containing all genome-wide
significant SNPs.
Mixed-effects analysis of hit regions (MolTWIN
1H NMR
data)
Underlying the observed data at a metabolite peak (i.e. across all
spectra) was a complex correlation structure, induced by the
sharing of alleles, individuals, and samples by different sample
aliquots. In the follow-up analysis of hit regions we explicitly
modelled this covariance structure while quantifying the metab-
olite’s association with each local SNP in turn (i.e. with each SNP
within 200 kb of the hit region and with MAF . 5%).
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tional assumptions, we mapped the quantiles of the empirical data
distribution at each peak to the quantiles of a standard Gaussian
distribution, yielding the transformed data vector, z. In contrast to
the genome-wide analysis described in the previous section (based
on the averaged data, y), technical and biological replicates were
not averaged for this analysis (instead, variation between replicates
was retained in z and modelled). We fitted the following mixed-
effects model:
zijkl~bgijzpb(i,j,k,l)ztt(i,k)zdizmz(i,j)zeijzwikzvijkzeijkl
where twin pairs were indexed by i[ 1,:::,77 fg , the twins within a
pair were indexed by j[ 1,2 fg , the visits of a twin pair were
indexed by k[ 1,2 fg , and the aliquots of a sample were indexed by
l[ 1,2 fg . The ‘fixed effects’ in the model were b, the pb, and t. The
additive effect of the SNP under consideration was modelled by b,
with gij[ 0,1,2 fg denoting the number of copies of the reference
allele possessed by twin j in pair i. The parameters
pb : b~1,:::,5 fg controlled for experimental inter-plate effects,
with b(:) mapping spectra to plates. The parameter t controlled
for sampling time-related effects, with t(:) in the equation above
mapping visits to sample-collection times (in 24-hour format; times
were mostly 10 or 14). The other terms in the model were ‘random
effects,’ which modelled the covariance structure across observa-
tions induced by familial (d,m), individual-environmental (e),
temporally dynamic (w,v), and non-biological (e) effects. Similarly
to [68], there was one mi term for each MZ pair and two such
terms, mi1 and mi2, for each DZ pair (i.e. z(i,j)~i if i was an MZ
pair, whilst z(i,j)~(i,j) if i was a DZ pair). Each ‘random effect’
followed a zero-mean Gaussian distribution with its corresponding
standard deviation from s~(sd,sm,se,sw,sv,se)’ (e.g. the di
independently followed p(dijsd)~Normal(dij0,s2
d)).
The current paper’s model induced a covariance structure on z
that was identical to that which is used in the standard methodology
for modelling twin data (see, e.g., [68–70]). In the parameterization
above, s2
dzs2
m modelled the familial variance (i.e. the variance
attributable to genetics and common environment), s2
e modelled the
individual-environmental variance. Additionally, our model included
variance parameters representing longitudinally unstable variation.
These (s2
w and s2
v) were referred to as the ‘common-visit’ and
‘individual-visit’ effects respectively, because they measured the
component ofphenotypic variationthat fluctuated betweenvisits, and
which was shared and non-shared respectively between twins; the
common-visit parameterization was included in the model because
twins visited the clinic in pairs. Finally, there was a parameter s2
e to
model experimental variation. In the variance decompositions of the
current paper (Figure 4 and Table 4), variances were expressed as
proportions of the total biological variance, which was defined as
Var(bgij)zs2
dzs2
mzs2
ezs2
wzs2
v,w h e r eVar(bgij) was the phe-
notypic variance explained by the corresponding mQTL SNP. The
biological variancedidnot include the experimental variance,s2
e,and
was therefore appropriate for comparing the properties of molecular
phenotypes across platforms when the level of experimental variation
on the platforms was not of primary interest.
For each SNP within 200 kb of the hit region, we fitted the
mixed-effects model both with and without the bgij term. From
these fitted models, we calculated the p-value for the test of the null
hypothesis that b~0, using {2logL as a test statistic (where L
denotes the likelihood ratio), and employing its asymptotic null
distribution (a chi-squared density with one degree of freedom).
These p-values are displayed in the text, Figure 1, Figure 2,
Figures S2 and S3, and Table 3, Tables S1 and S2A.
At the most strongly associated SNP, we went on to fit the
model in a Bayesian framework, quantifying the precision of
parameter estimates using posterior credible intervals. For this
analysis we used directly the log-transformed metabolite concen-
trations, denoted by x (see section on Data preprocessing and
feature extraction). For priors, we specified Uniform densities on
the standard deviation parameters in s (as discussed in [71]):
p(s)~Uniform(sj0,10|sx)
where sx denotes the sample standard deviation of the data, x. The
prior on the ‘fixed effects’ vector, a:(b,p’,t)’, was a diffuse
multivariate Gaussian distribution, with mean at the least squares
estimates, ^ a a, and diagonal covariance matrix with entries
100| max(x){min(x) ½  ðÞ
2. The results of fitting the model in
a Bayesian framework are summarized in Table 4 and Figure 4.
Replication of mQTL hits (MolOBB
1H NMR data)
For each of the mQTLs discovered in the MolTWIN cohort, we
re-tested the association using only data from the MolOBB cohort.
Specifically, we mapped the quantiles of the metabolite’s
concentration data to the corresponding quantiles of a standard
Gaussian distribution; we then tested for an additive association
with the corresponding SNP’s genotype data, including age and
gender as covariates in the linear model. Resulting p-values are
shown in Table 3.
Replication of Illig et al.’s mQTL hits (MolTWIN and
MolOBB Biocrates data)
We used the concentration data directly as output from the
Biocrates platform, and calculated metabolic traits from concen-
tration ratios as in [14]. We removed individuals overlapping with
the TwinsUK cohort used in [14], after which a total of 202
individuals were included in our Biocrates replication analysis (133
MolTWIN participants and 69 MolOBB participants). We fitted
similar models to those specified in the Materials and Methods
subsection ‘Mixed-effects analysis of hit regions,’ though now with
fixed effects for genotype (number of copies of reference allele),
plate, age, and gender. For each metabolic trait, the genotype data
in the model was from the single corresponding mQTL SNP as
reported in [14]. The results of the non-Bayesian analysis are
shown in Table 5 and the results of the Bayesian analysis are in
Table 4 and Figure 4.
Data availability
The data underlying the current paper’s analyses are available
for download from an FTP server (host: svilpaste.mii.lu.lv; login:
Moltwin_NMR; password: Moltwin_NMR1; path: /home/
George/PLoS_Genetics_mQTL_data).
Supporting Information
Figure S1 Peaks in urine
1H NMR spectra that are driven by
mQTL variation. In the bottom panel we plotted 50 spectra over a
subset of the ppm axis (note that, conventionally, the ppm axis is
plotted increasing from right to left). The top panels are zoomed-in
views of peaks from the three mQTL-driven urine metabolites of
the current paper. The vertical scale of the bottom panel differs
from the vertical scale shared by the top three panels.
(TIF)
Figure S2 Hit region for DMAp. Top: location of genes, with
rectangles denoting the position of exons. Middle: log-transformed
p-values ({log10(p)) for the test of association of the metabolite’s
mQTLs Exhibit Genetic Evidence of Selection
PLoS Genetics | www.plosgenetics.org 15 September 2011 | Volume 7 | Issue 9 | e1002270concentration with each SNP in the region. Bottom: LD between
each pair of SNPs in the region, with the colour scale for r2
superimposed.
(TIF)
Figure S3 Hit region for BAIBu. Top: location of genes, with
rectangles denoting the position of exons. Middle: log-transformed
p-values ({log10(p)) for the test of association of the metabolite’s
concentration with each SNP in the region. Bottom: LD between
each pair of SNPs in the region, with the colour scale for r2
superimposed.
(TIF)
Figure S4 Comparison of estimates of effect size of mQTL SNPs
for metabolic traits measured on the Biocrates platform. Effect
sizes are compared between Illig et al. (estimates are taken from
Table 1 of [14]), and the current paper’s replication of Illig et al.’s
findings. The comparison is made using proportions of total
phenotypic variance, because this was the measure of effect size
used in [14]. Where applicable, the posterior distribution of effect
size is represented as follows: the central tick in a box marks the
posterior mean, the ends of a box mark the posterior quartiles, and
the whiskers represent the central 95% credible interval (extending
to the 2.5 and 97.5 posterior percentiles).
(TIF)
Figure S5 Comparison of estimates of effect size of mQTL SNPs
on metabolite concentrations measured by
1H NMR. Effect sizes
are compared between the discovery stage (MolTWIN cohort) and
the replication stage (MolOBB cohort). The MolTWIN estimates
and credible intervals are as shown in Figure 4. The MolOBB
estimates had to be calculated differently to the MolTWIN
estimates because of the absence of technical replication in the
MolOBB cohort study design. To calculate the MolOBB
estimates, we first fitted a linear model with logarithmically
transformed metabolite concentration, x, as the response variable,
and with subjects’ age, gender, and mQTL SNP genotype
as explanatory variables—i.e. xi~mzb|giza|(age)izc|
2(gender)izei, where gi is the number of copies of the reference
allele at the mQTL SNP carried by subject i. From the model fit,
we estimated the proportion of total variance in metabolite
concentration explained by the SNP using the ratio of sample
variances: Var(^ b bgi)=Var(xi). We then rescaled this to be the
proportion of biological variation in metabolite concentration. This
was achieved by dividing by 1{^ p pe, where ^ p pe is the estimate (from
the MolTWIN cohort) of the proportion of total variance in x
explained by experimental variation (see Materials and Methods).
(TIF)
Figure S6 Distribution of the ratio of TMAOu concentration to
the combined concentration of TMAOu and TMAu (includes
both MolTWIN and MolOBB cohorts). Trimethylaminuria
controls have relatively high values of TMAOu/(TMAOu +
TMAu), typically greater than 0.8 [50], whilst values for cases are
considerably lower (the two cases examined in [50] have values
0.11 and 0.22).
(TIF)
Figure S7 Plot of spectra for which mQTL-driven metabolites,
labelled top, are determined as missing. Missing-peak spectra are
plotted in black. For comparison, an arbitrarily selected set of 25
present-peak spectra is plotted in grey. Vertical green lines delimit
the corresponding peak’s bin (Materials and Methods).
(TIF)
Table S1 Details of statistical association between each mQTL-
driven metabolite and the SNPs within 200 kb of its hit region.
Genomic locations are given in NCBI build 37 coordinates.
Columns labelled ‘Beta,’ ‘S.E. Beta’ (S.E. = standard error) and
‘p-value’ (for the test of the null hypothesis that b~0) give details
of the fit of the non-Bayesian mixed-effects model described in
section ‘Mixed-effects analysis of hit regions (MolTWIN
1H NMR
data)’ of Materials and Methods. The meaning of the column
‘Genome-Wide Significant’ is described in the final paragraph of
the section ‘Genome-wide association scan (MolTWIN
1H NMR
data)’ of Materials and Methods.
(XLS)
Table S2 (A) Non-synonymous SNPs in LD with mQTL SNPs.
(B) Corresponding residue changes and predicted functional effects
of non-synonymous SNPs.
(DOC)
Table S3 Previously discovered eQTLs within 200 kb of mQTL
hit regions.
(DOC)
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